Chinese Academy of Medical Sciences Peking Union Medical College Hospital

A novel dual-targeting radiopharmaceutical therapy targeting two cancer cell markers simultaneously demonstrated safety and efficacy in a first-in-human trial with nine advanced adenocarcinoma patients.

SCG Cell Therapy's Phase 1 trial of SCG101, an autologous HBV-specific TCR-T cell therapy, demonstrated sustained clearance of hepatitis B surface antigen in 94% of heavily pre-treated HBV-related liver cancer patients.

A phase 3 trial demonstrated that high-dose (54 Gy) hyper-fractionated twice-daily radiotherapy significantly improved overall survival to 60.7 months compared with 39.5 months for standard-dose (45 Gy) in limited-stage small cell lung cancer patients.

A 57-year-old female with a large gastrointestinal stromal tumor (GIST) achieved successful R0 resection after neoadjuvant ripretinib therapy, marking the first reported case of ripretinib use in this setting.

A Phase 2 study reveals that perioperative tislelizumab combined with neoadjuvant chemotherapy yields a 44% pathological complete response (pCR) rate in resectable ESCC.

In East Asian patients with high-risk, locally advanced cervical cancer, pembrolizumab plus concurrent chemoradiotherapy (CCRT) significantly improved progression-free survival (PFS).